New drugs to activate p53 for cancer treatment
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
This study is looking at new ways to help cancer patients by using small molecules to turn back on a key protein called p53 that helps control cell growth, which is often turned off in cancer cells, and they hope this will lead to better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11009551 on NIH RePORTER |
What this research studies
This research focuses on developing new small molecule inhibitors that target USP7 to reactivate the p53 tumor suppressor pathway in cancer cells. Many cancers retain a functional p53 gene, but its activity is often suppressed, leading to uncontrolled cell growth. By inhibiting USP7, the researchers aim to restore p53 function, potentially improving cancer treatment outcomes. The approach builds on previous successes with Mdm2 inhibitors but seeks to overcome challenges related to toxicity and resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients whose tumors retain wild-type p53 but have downregulated its activity.
Not a fit: Patients with cancers that have mutated p53 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that harness the body's own tumor suppression mechanisms.
How similar studies have performed: Previous research has shown promise with Mdm2 inhibitors, but this approach with USP7 inhibitors is relatively novel and untested in clinical settings.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Gu, Wei — Columbia University Health Sciences
- Study coordinator: Gu, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.